Petros Pharmaceuticals, Inc.
PTPI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001815903
No open-market purchases or sales by Petros Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Petros Pharmaceuticals, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +2 vs. Q1 2021
- Shares held
- 963.6K
- −173.1K (−15.2%) vs. Q1 2021
- Total value
- $3.02M
- −$1.22M (−28.8%) vs. Q1 2021
- New holders
- 6
- 6 more added
- Sold out
- 4
- 5 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTPI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 15 | $77.6K |
| Q4 2024 | 9 | $38.5K |
| Q3 2024 | 11 | $59.2K |
| Q2 2024 | 12 | $94.9K |
| Q1 2024 | 13 | $94.9K |
| Q4 2023 | 16 | $164.7K |
| Q3 2023 | 14 | $170.6K |
| Q2 2023 | 14 | $214.3K |
| Q1 2023 | 9 | $42.7K |
| Q4 2022 | 10 | $90.6K |
| Q3 2022 | 13 | $355.0K |
| Q2 2022 | 16 | $558.0K |
| Q1 2022 | 19 | $1.30M |
| Q4 2021 | 21 | $3.58M |
| Q3 2021 | 19 | $1.82M |
| Q2 2021 | 22 | $3.02M |
| Q1 2021 | 20 | $4.23M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Petros Pharmaceuticals, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Shay Capital LLC | 238,764 | $747.0K | 0.18% | −17,906−7.0% | Reduced |
| NorthRock Partners, LLC | 219,188 | $686.0K | 0.06% | −118,343−35.1% | Reduced |
| Vanguard Group Inc | 107,500 | $336.0K | 0.00% | +18,796+21.2% | Added |
| CM Management, LLC | 100,000 | $313.0K | 0.23% | +55,000+122.2% | Added |
| Renaissance Technologies LLC | 54,887 | $172.0K | 0.00% | −130,658−70.4% | Reduced |
| Acorn Financial Advisory Services Inc | 50,200 | $157.0K | 0.05% | −12,500−19.9% | Reduced |
| Platform Technology Partners | 44,000 | $138.0K | 0.06% | +44,000 | New |
| Citadel Advisors LLC | 35,062 | $110.0K | 0.00% | −430−1.2% | Reduced |
| Emfo, LLC | 28,000 | $88.0K | 0.08% | +28,000 | New |
| Geode Capital Management, LLC | 23,725 | $74.0K | 0.00% | +9,545+67.3% | Added |
| Neville Rodie & Shaw Inc | 21,875 | $68.0K | 0.01% | 00.0% | Unchanged |
| BlackRock Inc. | 18,938 | $59.0K | 0.00% | +661+3.6% | Added |
| Virtu Financial LLC | 14,364 | $45.0K | 0.00% | +14,364 | New |
| Advisor Group Holdings, Inc. | 2,495 | $8.00K | 0.00% | +600+31.7% | Added |
| Royal Bank of Canada | 2,000 | $6.00K | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 1,200 | $4.00K | 0.00% | +1,200 | New |
| UBS Group AG | 943 | $3.00K | 0.00% | +943 | New |
| Morgan Stanley | 169 | $1.00K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 34 | $0 | 0.00% | +23+209.1% | Added |
| Wells Fargo & Company | 28 | $0 | 0.00% | 00.0% | Unchanged |
| First Manhattan Co | 100 | $0 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 89 | $0 | 0.00% | +89 | New |
| Spire Wealth Management | 0 | $0 | 0.00% | −44,000−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Brewin Dolphin Ltd | 0 | $0 | 0.00% | −2,143−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −340−100.0% | Sold out |